Embryonal rhabdomyosarcoma is driven by oncogenic driver mutations like RAS and TP53 mutations, whereas alveolar rhabdomyosarcoma is most often characterised by a fusion protein, resulting from a genomic translocation (mostly PAX3-FOXO1 or PAX7-FOXO1). The gene discussed is FOXO1; the disease is embryonal rhabdomyosarcoma.